CD27 and neoplasm: Given that high doses of anti-CD3/CD28 treatment downregulated the expression of CD27 and CD28 (figure 5A, B), we postulated that lowering TCR stimulation—below a level that does not trigger DP to DN transition—would be crucial to maintain constantly high levels of these costimulatory molecules throughout Temra differentiation during tumor progression.